Table 6. Vaccine Procurement .
| Countries | Income Level | Dose Purchase Per Inhabitant |
Total Doses Purchase
(Million) |
Pfizer
(Million) |
Oxford-Astraz.
(Million) |
Moderna
(Million) |
Janssen
(Million) |
Novavax
(Million) |
Sanofi-GSK
(Million) |
Others (Gamaleya, Sinopharm, Sinovac) (Million) | COVAX Status | COVAX - Doses Allocated (Million) |
| Canada | HIC | 10.44 | 364 | 105 | 23 | 44 | 10 | 52 | 72 | 0 | Self-financing | 1.7 |
| UK | HIC | 8.18 | 517 | 100 | 100 | 17 | 30 | 60 | 60 | 0 | Self-financing | 0.5 |
| EU | HIC | 6.89 | 2850 | 1500 | 300 | 310 | 200 | 0 | 300 | 0 | Donor | 0 |
| New Zeeland | HIC | 6.57 | 30 | 10 | 8 | 0 | 2 | 11 | 0 | 0 | Self-financing | 0.3 |
| Australia | HIC | 5.82 | 170 | 40 | 53 | 25 | 0 | 51 | 0 | 0 | Self-financing | 0.5 |
| Chile | HIC | 5.07 | 90 | 10 | 14 | 0 | 0 | 0 | 0 | 60.0 | Self-financing | 0.8 |
| Israel | HIC | 4.53 | 41 | 17 | 10 | 10 | 0 | 0 | 0 | 0 | Self-financing | 0 |
| USA | HIC | 3.99 | 1200 | 300 | 300 | 300 | 100 | 110 | 100 | 0 | Donor | - |
| Switzerland | HIC | 3.67 | 31 | 6 | 0 | 20 | 0 | 0 | 0 | 0 | Self-financing | 0 |
| South Korea | HIC | 3.44 | 172 | 66 | 20 | 40 | 6 | 40 | 0 | 0 | Self-financing | 0 |
| Bolivia | LMIC | 3.40 | 24 | 0 | 5 | 0 | 15 | 0 | 0 | 4.5 | AMC | 0.2 |
| Japan | HIC | 2.88 | 364 | 194 | 120 | 50 | 0 | 0 | 0 | 0 | Self-financing | 0 |
| Turkey | UMIC | 2.57 | 214 | 64 | 0 | 0 | 0 | 0 | 0 | 50.0 | Not involved | - |
| Morocco | LMIC | 2.50 | 91 | 0 | 50 | 0 | 0 | 0 | 0 | 0 | AMC | 1.7 |
| Brazil | UMIC | 2.31 | 450 | 200 | 102 | 0 | 38 | 0 | 0 | 10.0 | Self-financing | 5.0 |
| Malaysia | UMIC | 2.18 | 66 | 25 | 6 | 0 | 0 | 0 | 0 | 6.0 | Self-financing | 1.4 |
Abbreviations: COVAX, COVID-19 Vaccine Global Access; HIC, High-income country; UMIC, upper-middle-income country; LMIC, low- and middle-income country; LIC, low-income country; AMC, Advanced Market Commitment for COVID-19 vaccine access.